Jan 31
Registration statement
S-1
Registration statement
ACXP · Acurx Pharmaceuticals, Inc. · Documents
$0.99
-0.05 (-4.37%)
At close · Nov 12
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”View the 10-Q filed Aug 13, 2026
Market Cap
$5.97M
Shares
6.06M
Volume · Nov 12
159.19K
Avg daily vol (3M)
124.59K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2025
Jan 7
Current report
8-K
Events of Jan 6
Entered into a material agreement, Unregistered sale of equity, Other events
2024
Nov 13
Earnings call
Q3 2024 earnings call
Nov 13
Current report
8-K
Financial results
Nov 12
Quarterly report
10-Q
FY2024 Q3, ended Sep 30
Quarterly report for FY2024 Q3
Net loss $2.82M
Diluted EPS -$0.17
Aug 9
Earnings call
Q2 2024 earnings call
Aug 9
Current report
8-K
Financial results
Aug 8
Quarterly report
10-Q
FY2024 Q2, ended Jun 30
Quarterly report for FY2024 Q2
Net loss $4.12M
Diluted EPS -$0.26
Jun 17
Current report
8-K
Shareholder vote results
May 15
Earnings call
Q1 2024 earnings call
May 15
Current report
8-K
Financial results
May 14
Quarterly report
10-Q
FY2024 Q1, ended Mar 31
Quarterly report for FY2024 Q1
Net loss $4.38M
Diluted EPS -$0.28
Apr 29
Proxy statement
DEF 14A
Meeting Jun 17, 2024
Proxy statement
Apr 29
Annual report to holders
ARS
Annual report to holders
Apr 29
Proxy statement
DEFA14A
Proxy statement
Mar 29
Registration statement
S-1/A
Registration statement
Mar 18
Earnings call
Q4 2023 earnings call
Mar 18
Current report
8-K
Financial results
Mar 18
Registration statement
S-1
Registration statement
Mar 15
Annual report
10-K
FY2023, ended Dec 31
Annual report for FY2023
Net loss $14.58M
Diluted EPS -$1.15
2023
Nov 15
Current report
8-K
Entered into a material agreement
Nov 14
Earnings call
Q3 2023 earnings call
Nov 14
Current report
8-K
Financial results
Nov 13
Quarterly report
10-Q
FY2023 Q3, ended Sep 30
Quarterly report for FY2023 Q3
Net loss $3.11M
Diluted EPS -$0.24
Nov 3
Current report
8-K
Events of Nov 2
Other events
Oct 2
Current report
8-K
Other events
Aug 14
Earnings call
Q2 2023 earnings call
Aug 14
Current report
8-K
Financial results
Aug 11
Quarterly report
10-Q
FY2023 Q2, ended Jun 30
Quarterly report for FY2023 Q2
Net loss $3.45M
Diluted EPS -$0.28
Jun 29
Registration statement
S-1
Registration statement
Jun 20
Current report
8-K
Events of Jun 15
Charter or bylaw amendment, or fiscal year change, Shareholder vote results
May 17
Current report
8-K
Events of May 16
Entered into a material agreement, Unregistered sale of equity, Change to shareholders' rights
May 12
Quarterly report
10-Q
FY2023 Q1, ended Mar 31
Quarterly report for FY2023 Q1
Net loss $2.9M
Diluted EPS -$0.25
Apr 27
Proxy statement
DEF 14A
Meeting Jun 15, 2023
Proxy statement
Apr 27
Annual report to holders
ARS
Annual report to holders
Apr 27
Proxy statement
DEFA14A
Proxy statement
Apr 17
Proxy statement
PRE 14A
Meeting Jun 15, 2023
Proxy statement
Mar 31
Earnings call
Q1 2023 earnings call
Mar 16
Earnings call
Q4 2022 earnings call
Mar 16
Current report
8-K
Financial results, Other events
Mar 15
Annual report
10-K
FY2022, ended Dec 31
Annual report for FY2022
Net loss $12.09M
Diluted EPS -$1.12
2022
Nov 14
Earnings call
Q3 2022 earnings call
Nov 14
Current report
8-K
Financial results
Nov 10
Quarterly report
10-Q
FY2022 Q3, ended Sep 30
Quarterly report for FY2022 Q3
Net loss $3.54M
Diluted EPS -$0.32
Sep 14
Registration statement
S-1
Registration statement
Aug 15
Earnings call
Q2 2022 earnings call
Aug 15
Current report
8-K
Financial results
Aug 12
Quarterly report
10-Q
FY2022 Q2, ended Jun 30
Quarterly report for FY2022 Q2
Net loss $2.62M
Diluted EPS -$0.26
Jul 25
Jul 1
Registration statement
S-3
Registration statement
Showing 51–100 of 117 documents
Key facts
CIK
1736243
CUSIP
00510M203
13F (30d)
10 filings
10 filers
Visit website
Investor relations